BioCentury | Feb 4, 2013
Company News

Questcor management update

...corporate strategic development, a newly created position, formerly CEO, managing director and a director of Xenome Ltd. WIR...
BioCentury | Sep 3, 2012
Company News

Qiagen, Trovagene deal

Trovagene (formerly Xenomics Inc. ) received an undisclosed milestone payment from Qiagen's Ipsogen S.A. subsidiary under a 2007 deal granting Ipsogen co-exclusive, worldwide rights, outside of China and India, to use IP covering nucleophosmin ( NPM1 ;...
BioCentury | Aug 23, 2012
Company News

Senz debuts with seed financing

...Allyence Research Inc. (Menlo Park, Calif.). Senz was founded in February by former colleagues at Xenome Ltd....
...Brisbane, Australia) -- Anthony Filippis and Ian Nisbet. Filippis was VP of business development at Xenome...
BioCentury | Aug 15, 2011
Finance

Highlights of weekly biotech stock moves

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) was off $1.48 (58%) to $1.06 on Wednesday after receiving a complete response letter from FDA for an NDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC)....
BioCentury | Aug 15, 2011
Company News

Sequenom, Trovagene deal

TrovaGene (formerly Xenomics Inc. ) said a 2008 deal that gave Sequenom rights to TrovaGene's transrenal technology was terminated. TrovaGene regains rights to patents covering transrenal fetal nucleic acids found in maternal urine for noninvasive prenatal...
BioCentury | Aug 11, 2011
Company News

TrovaGene, Sequenom deal terminated

TrovaGene Inc. (Pink:TROV) said a 2008 deal that gave Sequenom Inc. (NASDAQ:SQNM) rights to TrovaGene's transrenal technology has been terminated. TrovaGene (formerly Xenomics Inc. ) did not disclose details. TrovaGene regains rights to patents covering transrenal...
BioCentury | Aug 23, 2010
Regulation

Run off the road

...lower back pain. He would put neuropathy in the middle. Michael Aldridge, executive director of Xenome Ltd....
...And there are good models for acute pain, especially for post-orthopedic surgeries," he told BioCentury. Xenome...
...Texas M.D. Anderson Cancer Center , Houston, Texas Vanderbilt University Medical Center , Nashville, Tenn. Xenome Ltd....
BioCentury | Mar 29, 2010
Company News

Xenome, AstraZeneca deal

...deal to screen Xenome's xdiscover peptide library to discover drug candidates against two pain targets. Xenome...
...eligible for milestones and royalties. Further details were not disclosed (see BioCentury, Jan. 19, 2009). Xenome Ltd....
BioCentury | Feb 18, 2010
Distillery Therapeutics

Indication: Indication

...norepinephrine transporter and NMDARs, has completed Phase IIb testing to treat diabetic peripheral neuropathic pain. Xenome Ltd.'s...
BioCentury | Dec 21, 2009
Company News

Sequenom, Xenomics diagnostic news

Xenomics said it believes that Sequenom willfully manipulated data for the SEQureDx Down syndrome test to induce Xenomics into a 2008 deal. Earlier this year, Sequenom announced a delay for its SEQureDx Down syndrome test...
Items per page:
1 - 10 of 72
BioCentury | Feb 4, 2013
Company News

Questcor management update

...corporate strategic development, a newly created position, formerly CEO, managing director and a director of Xenome Ltd. WIR...
BioCentury | Sep 3, 2012
Company News

Qiagen, Trovagene deal

Trovagene (formerly Xenomics Inc. ) received an undisclosed milestone payment from Qiagen's Ipsogen S.A. subsidiary under a 2007 deal granting Ipsogen co-exclusive, worldwide rights, outside of China and India, to use IP covering nucleophosmin ( NPM1 ;...
BioCentury | Aug 23, 2012
Company News

Senz debuts with seed financing

...Allyence Research Inc. (Menlo Park, Calif.). Senz was founded in February by former colleagues at Xenome Ltd....
...Brisbane, Australia) -- Anthony Filippis and Ian Nisbet. Filippis was VP of business development at Xenome...
BioCentury | Aug 15, 2011
Finance

Highlights of weekly biotech stock moves

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) was off $1.48 (58%) to $1.06 on Wednesday after receiving a complete response letter from FDA for an NDA for Exelbine vinorelbine injectable emulsion to treat non-small cell lung cancer (NSCLC)....
BioCentury | Aug 15, 2011
Company News

Sequenom, Trovagene deal

TrovaGene (formerly Xenomics Inc. ) said a 2008 deal that gave Sequenom rights to TrovaGene's transrenal technology was terminated. TrovaGene regains rights to patents covering transrenal fetal nucleic acids found in maternal urine for noninvasive prenatal...
BioCentury | Aug 11, 2011
Company News

TrovaGene, Sequenom deal terminated

TrovaGene Inc. (Pink:TROV) said a 2008 deal that gave Sequenom Inc. (NASDAQ:SQNM) rights to TrovaGene's transrenal technology has been terminated. TrovaGene (formerly Xenomics Inc. ) did not disclose details. TrovaGene regains rights to patents covering transrenal...
BioCentury | Aug 23, 2010
Regulation

Run off the road

...lower back pain. He would put neuropathy in the middle. Michael Aldridge, executive director of Xenome Ltd....
...And there are good models for acute pain, especially for post-orthopedic surgeries," he told BioCentury. Xenome...
...Texas M.D. Anderson Cancer Center , Houston, Texas Vanderbilt University Medical Center , Nashville, Tenn. Xenome Ltd....
BioCentury | Mar 29, 2010
Company News

Xenome, AstraZeneca deal

...deal to screen Xenome's xdiscover peptide library to discover drug candidates against two pain targets. Xenome...
...eligible for milestones and royalties. Further details were not disclosed (see BioCentury, Jan. 19, 2009). Xenome Ltd....
BioCentury | Feb 18, 2010
Distillery Therapeutics

Indication: Indication

...norepinephrine transporter and NMDARs, has completed Phase IIb testing to treat diabetic peripheral neuropathic pain. Xenome Ltd.'s...
BioCentury | Dec 21, 2009
Company News

Sequenom, Xenomics diagnostic news

Xenomics said it believes that Sequenom willfully manipulated data for the SEQureDx Down syndrome test to induce Xenomics into a 2008 deal. Earlier this year, Sequenom announced a delay for its SEQureDx Down syndrome test...
Items per page:
1 - 10 of 72